Authors | Aim | Sample | Methods | Instruments | Results |
---|---|---|---|---|---|
Shimizu et al. [10] | Determine how BDNF levels are related to treated and untreated depressive conditions and how these levels differ between individuals with MDD and controls. | 16 individuals with MDD without antidepressant treatment. 17 individuals with MDD on antidepressant therapy. 50 controls. |
Patients were assessed using the Hamilton Scale for depression (HAM-D). BDNF levels were accessed through the ELISA method. | Hamilton Depression Rating Scale (HAM-D) | Low levels of BDNF were found in untreated depressive patients when compared to the treatment group and the control group. |
Siuciak et al. [34] | Determine how the administration of BDNF can produce an antidepressant effect in two animal models of depression. | Male rats treated in the laboratory. | Infusion of BDNF into the animals' brains for a week. | - | An antidepressant effect was observed after administration of BDNF in the two animal models of depression tested in the study. The increase could be mediated by increased activity in monoaminergic systems. |
Martinotti et al. [5] | Investigate the effects of Agomelatine on serum BDNF levels in a sample of depressed patients. | 27 individuals with MDD. | Serum levels of BDNF were achieved by the ELISA method at the beginning of treatment after two weeks and after 8 weeks of treatment. | Hamilton Depression Rating Scale (HAM-D). Snaith-Hamilton Pleasure Scale. |
Patients showed an increase in BDNF levels after two weeks of treatment with Agomelatine. |